The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

A key advantage of the drug is its oral route of administration, offering patients a more convenient alternative to ...

EMA encourages NAMs to replace animal testing, aligning with 3Rs principles, and has published a concept paper on regulatory ...

"Tevimbra is already approved in the EU across multiple settings in [non-small cell lung cancer], the most common form of lung cancer, and this positive CHMP opinion expands its potential to help ...

The U.S. Food and Drug Administration (FDA) announced on Friday, after market close, that it is investigating the death of an ...

GOTHENBURG, SWEDEN / ACCESS Newswire / July 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV). The XVIVO Heart Assist Transport and the XVIVO Heart Assist Transport Perfusion Set have recei ...

Trump says spoke to Thai, Cambodia leaders after ceasefire Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines, ...

EMA committee recommends approval of Eli Lilly’s donanemab in early symptomatic Alzheimer's disease: Indianapolis Monday, July 28, 2025, 13:00 Hrs [IST] Eli Lilly and Company an ...

Recommendation based on Phase 3 RATIONALE-315 study, in which TEVIMBRA demonstrated clinically meaningful and statistically significant improvement in event-free survival and major pathological respon ...

Under terms of the deal, Bavarian Nordic shareholders will receive an all-cash offer at a premium, with plans to delist the ...

The trial drug Trontinemab is designed to bypass the blood brain barrier, delivering more treatment directly to the brain.

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, as a part of the company's growing development programmefor the ...